Severe neutropenia after rituximab-treatment of multiple sclerosis

Tietueen suppeat tiedot
dc.contributor.authorEero Rissanen
dc.contributor.authorKari Remes
dc.contributor.authorLaura Airas
dc.contributor.organizationfi=PET-keskus|en=Turku PET Centre|
dc.contributor.organizationfi=kliininen laitos|en=Department of Clinical Medicine|
dc.contributor.organizationfi=kliiniset neurotieteet|en=Clinical Neurosciences|
dc.contributor.organizationfi=sisätautioppi|en=Internal Medicine|
dc.contributor.organizationfi=tyks, vsshp|en=tyks, varha|
dc.contributor.organization-code1.2.246.10.2458963.20.40502528769
dc.contributor.organization-code1.2.246.10.2458963.20.61334543354
dc.contributor.organization-code1.2.246.10.2458963.20.74845969893
dc.converis.publication-id28985130
dc.converis.urlhttps://research.utu.fi/converis/portal/Publication/28985130
dc.date.accessioned2022-10-28T13:10:29Z
dc.date.available2022-10-28T13:10:29Z
dc.description.abstract<p>We present here the first MS-case where rituximab-treatment led to grade IV <a href="https://www.sciencedirect.com/topics/medicine-and-dentistry/neutropenia" title="Learn more about Neutropenia">neutropenia</a>, with hospitalization and treatment of a serious infection with <a href="https://www.sciencedirect.com/topics/medicine-and-dentistry/broad-spectrum-antibiotic" title="Learn more about Broad-spectrum antibiotic">broad-spectrum antibiotics</a>. The neutropenia resolved promptly with granulocyte-colony stimulating factor-treatment and the patient recovered well. Due to risk of recurring neutropenia rituximab-treatment was not re-administered. We discuss the mechanisms and occurrence of neutropenia as a side effect to rituximab-treatment of MS, and remind of the importance of monitoring rituximab-treated MS-patients for this rare but potentially dangerous side effect.<br /></p>
dc.format.pagerange3
dc.format.pagerange5
dc.identifier.jour-issn2211-0348
dc.identifier.olddbid180234
dc.identifier.oldhandle10024/163328
dc.identifier.urihttps://www.utupub.fi/handle/11111/38219
dc.identifier.urnURN:NBN:fi-fe2021042713409
dc.language.isoen
dc.okm.affiliatedauthorRissanen, Eero
dc.okm.affiliatedauthorRemes, Kari
dc.okm.affiliatedauthorAiras, Laura
dc.okm.affiliatedauthorDataimport, tyks, vsshp
dc.okm.affiliatedauthorDataimport, 2609820 PET Tutkimus
dc.okm.discipline3124 Neurology and psychiatryen_GB
dc.okm.discipline3124 Neurologia ja psykiatriafi_FI
dc.okm.internationalcopublicationnot an international co-publication
dc.okm.internationalityInternational publication
dc.okm.typeA1 ScientificArticle
dc.publisherElsevier B.V.
dc.relation.doi10.1016/j.msard.2017.12.005
dc.relation.ispartofjournalMultiple Sclerosis and Related Disorders
dc.relation.volume20
dc.source.identifierhttps://www.utupub.fi/handle/10024/163328
dc.titleSevere neutropenia after rituximab-treatment of multiple sclerosis
dc.year.issued2018

Tiedostot

Näytetään 1 - 1 / 1
Name:
RTX_MS_neutropenia_case 28.10.17_Final.doc
Size:
100 KB
Format:
Microsoft Word
Description:
Final draft
Lataa

Kokoelmat

Rinnakkaistallenteet